Juliet Shih1, Heather Leutwyler1, Christine Ritchie2, Steven M Paul1, Jon D Levine2, Bruce Cooper1, Fay Wright3, Yvette P Conley4, Christine Miaskowski5,6. 1. School of Nursing, University of California, San Francisco, CA, USA. 2. School of Medicine, University of California, San Francisco, CA, USA. 3. School of Nursing, Yale University, New Haven, CT, USA. 4. School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA. 5. School of Nursing, University of California, San Francisco, CA, USA. chris.miaskowski@ucsf.edu. 6. Department of Physiological Nursing, University of California, Box 0610 - N631Y, San Francisco, CA, 94143-0610, USA. chris.miaskowski@ucsf.edu.
Abstract
PURPOSE: Between 14 and 85 % of patients report noticeable changes in cognitive function during chemotherapy (CTX). The purposes of this study were to determine which demographic, clinical, and symptom characteristics were associated with inter-individual variability in initial levels of attentional function as well as with changes in the trajectories of attentional function in a sample of oncology patients who received two cycles of CTX. METHODS: Oncology outpatients (n = 1329) were recruited from two comprehensive cancer centers, one veteran's affairs hospital, and four community-based oncology programs. The Attentional Function Index (AFI) was used to assess perceived effectiveness in completing daily tasks that required working memory and attention. Hierarchical linear modeling (HLM) was used to evaluate for inter-individual variability in initial levels and in the trajectories of attentional function. RESULTS: Demographic, clinical, and symptom characteristics associated with inter-individual differences of attentional function at enrollment (i.e., intercept) were as follows: employment status, functional status, trait anxiety, depressive symptoms, sleep disturbance, evening fatigue, and morning energy. Gender was the only characteristic associated with inter-individual differences in the trajectories of attentional function. Morning fatigue was the only characteristic associated with both initial levels and the trajectories of attentional function. CONCLUSIONS: Prior to their next dose of CTX, patients reported moderate levels of attentional function that persisted over two cycles of CTX. Many of the clinical and symptom characteristics associated with decrements in attentional function are amenable to interventions. Clinicians need to assess patients for changes in attentional function and associated characteristics and recommend evidence-based interventions.
PURPOSE: Between 14 and 85 % of patients report noticeable changes in cognitive function during chemotherapy (CTX). The purposes of this study were to determine which demographic, clinical, and symptom characteristics were associated with inter-individual variability in initial levels of attentional function as well as with changes in the trajectories of attentional function in a sample of oncology patients who received two cycles of CTX. METHODS: Oncology outpatients (n = 1329) were recruited from two comprehensive cancer centers, one veteran's affairs hospital, and four community-based oncology programs. The Attentional Function Index (AFI) was used to assess perceived effectiveness in completing daily tasks that required working memory and attention. Hierarchical linear modeling (HLM) was used to evaluate for inter-individual variability in initial levels and in the trajectories of attentional function. RESULTS: Demographic, clinical, and symptom characteristics associated with inter-individual differences of attentional function at enrollment (i.e., intercept) were as follows: employment status, functional status, trait anxiety, depressive symptoms, sleep disturbance, evening fatigue, and morning energy. Gender was the only characteristic associated with inter-individual differences in the trajectories of attentional function. Morning fatigue was the only characteristic associated with both initial levels and the trajectories of attentional function. CONCLUSIONS: Prior to their next dose of CTX, patients reported moderate levels of attentional function that persisted over two cycles of CTX. Many of the clinical and symptom characteristics associated with decrements in attentional function are amenable to interventions. Clinicians need to assess patients for changes in attentional function and associated characteristics and recommend evidence-based interventions.
Authors: John D Merriman; Catherine Jansen; Theresa Koetters; Claudia West; Marylin Dodd; Kathryn Lee; Steven M Paul; Bradley E Aouizerat; Bruce A Cooper; Patrick S Swift; William Wara; Christine Miaskowski Journal: Oncol Nurs Forum Date: 2010-07 Impact factor: 2.172
Authors: Christine Miaskowski; Steven M Paul; Bruce A Cooper; Kathryn Lee; Marylin Dodd; Claudia West; Bradley E Aouizerat; Patrick S Swift; William Wara Journal: J Pain Symptom Manage Date: 2008-03-20 Impact factor: 3.612
Authors: Florence Joly; Bénédicte Giffard; Olivier Rigal; Michiel B De Ruiter; Brent J Small; Martine Dubois; Johan LeFel; Sanne B Schagen; Tim A Ahles; Jeffrey S Wefel; Janette L Vardy; Véronique Pancré; Marie Lange; Hélène Castel Journal: J Pain Symptom Manage Date: 2015-09-05 Impact factor: 3.612
Authors: Manuel Montero-Odasso; Louis Bherer; Stephanie Studenski; Karen Gopaul; Afua Oteng-Amoako; Sarah Woolmore-Goodwin; Paul Stoole; Jennie Wells; Timothy Doherty; Aleksandra A Zecevic; David Galinsky; R Jane Rylett; Jeffrey Jutai; Susan Muir-Hunter; Mark Speechley; Richard Camicioli Journal: Can Geriatr J Date: 2015-09-30